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1. Introduction 
Perimyocarditis is an acute inflammation of the pericardium and the underlying myocardium 
resulting in myocellular damage. It can simply be considered as acute pericarditis with 
elevated cardiac biomarkers. The coexistence of acute myocarditis and pericarditis is not 
uncommon since both are commonly caused by cardiotropic viruses. The 2 terms 
“perimyocarditis” and “myopericarditis” are used to describe the disease. While 
perimyocarditis implies predominant myocardial involvement and myopericarditis implies 
predominant pericardial involvement, both terms are used interchangeably without specific 
reference to the type of cardiac involvement. There is a wide spectrum of clinical presentations 
reflecting the extent of myocardial involvement ranging from asymptomatic cases with 
spontaneous recovery, to mild cases where symptoms are masked by the existing illness, to 
more severe cases complicated with heart failure necessitating inotropic support or even 
cardiac transplantation. Due to detrimental complications of acute myocarditis including left 
ventricular dysfunction and ventricular arrhythmias the diagnosis of myocarditis is more 
important and should be thoroughly looked for. Monitoring of the cardiac biomarkers is 
therefore mandatory in every patient presenting with clinical picture and electrocardiographic 
(EKG) evidence of acute pericarditis to exclude an underlying myocarditis. Acute pericarditis 
can present with ST segment elevation which can sometimes be focal rather than diffuse. In 
this scenario, chest pain associated with focal ST segment elevation and elevated cardiac 
biomarkers (if myocarditis co-existed) can mimic transmural myocardial infarction. 
Differentiation between both entities is of utmost importance to avert the un-necessary 
utilization of thrombolytic therapy which can be deleterious in perimyocarditis or to avoid 
missing a more serious diagnosis of ST segment elevation myocardial infarction (STEMI). 
After hospital discharge, patients should be followed for several weeks to exclude the 
development of heart failure or subclinical left ventricular dysfunction. 
2. Etiology 
Similar to myocarditis, perimyocarditis is most commonly of viral aetiology and less likely 
due to bacterial infection. Viral etiologies are predominately due to the coxsackie B virus, 
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however, other viruses have been incriminated including cytomegalovirus [1], parvovirus B 
19 [2], Epestein-Barr virus [3], Rubella [4], influenza A virus [5] and during hepatitis A virus 
infection [6]. The most famous bacterial pathogens associated with perimyocarditis are 
Borrelia burgderferi [7] and Campylobacter jejuni [8]. Others include Mycoplasma 
pneumonia [9], Chlamydia pneumonia, [10], Brucella [11], Rickettsia Helvetica [12], Yersinia 
enterocolitica [13], rickettsial Q fever [14], Shigella boydii [15], Shigella sonnei [16], 
tuberculosis [17], following Streptococcal tonsillitis [18] and Meningococcal septicemia[19]. 
The protozoan Toxoplasma gondii has also been described as a cause [20]. Immunizations 
have also been linked with perimyocarditis. The Smallpox vaccine has received great 
attention especially after its reinstitution for military personnel in 2002 and the report of 50 
cases of perimyocarditis [21, 22]. There are several reported cases of perimyocarditis that 
developed hours after Diphtheria-Tetanus-acellular Pertussis (DTaP) vaccination [23, 24]. 
Perimyocarditis has also been linked to the administration of certain drugs including 
meselazine used in the treatment of inflammatory bowel disease [25]. Table 1 represents a 
compilation of reported etiologies of perimyocarditis. 
 
Etiology of perimyocarditis
Viral pathogens 
 
Coxsackie B virus
Cytomegalovirus 
Parvovirus B19 
Epestein barr virus 
Rubella 
Influenza A virus 
Hepatitis A virus 
 
Bacterial pathogens 
 
Borrelia burgderferi
Campylobacter jejuni 
Mycoplasma pneumonia 
Chlamydia pneumonia 
Brucella 
Rickettsia Helvetica 
Yersinia enterocolitica 
Rickettsial q fever 
shigella boydii 
Shigella sonnei 
Tuberculosis 
Following streptococcal tonsiliitis  
Following meningococcal septicemia 
Protozoa 
 
Toxoplasma gondii
 
Immunizations 
 
 
Smallpox vaccine
Diphtheria-tetanus-acellular pertussis (DTaP) 
vaccination 
tetanus vaccination alone 
Immunologic/Connective tissue disease Sarcoidosis
Rheumatoid arthritis 
Systemic lupus erythematosus 
Acute rheumatic fever
Drug induced 
 
Meselazine
Methydolpa 
Sulphonamide 
Cocaine 
Table 1. Causes of perimyocarditis. 
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3. Clinical picture 
Perimyocarditis has a wide spectrum of presentation with some cases being asymptomatic, 
some suffering from symptoms of the preceding viral illness and some presenting with 
acute heart failure and cardiogenic shock as in cases with fulminant myocarditis. 60% of the 
cases have constitutional symptoms including fever, arthralgia, malaise and chills. In 35% of 
the cases, there is chest pain which is usually mild, persistent, stitching, worsens with deep 
inspiration or coughing and radiates specifically to the trapezius ridge. Chest pain can 
sometimes be severe raising the suspicion of myocardial infarction which is always in the 
differential. Patients may also present with palpitations, syncope, Stokes-Adams attacks or 
sudden death due to arrhythmias including ventricular tachycardia and variable degrees of 
conduction abnormalities. Careful history taking is mandatory with specific reference to the 
patient’s age, underlying medical problems including diabetes mellitus, hypertension, 
dyslipidemia, smoking history, positive family history of coronary artery disease and 
cocaine abuse that can place the patient at risk for myocardial ischemia. Clinical 
examination may be irrelevant with non-specific features as fever and tachycardia being the 
only positive clinical findings. Other clues in examination include a pericardial friction rub, 
however, only a minority of patients have pericardial rub on exam which tends to be 
transient and variable [26, 27]. A study of a cohort of patients with acute pericarditis 
confirmed poor sensitivity of a pericardial friction rub, which was found in only 35% of the 
cases [26]. Signs of decompensated heart failure (e.g. S3 gallop, elevated jugular venous 
pressure, lower limb edema and pulmonary congestion) can be detected in patients with 
fulminant myocarditis.  
4. Cardiac biomarkers and other laboratory tests 
Laboratory investigations in perimyocarditis can reveal elevated white blood cell count 
(WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and Brain natriuretic 
peptide (BNP) levels. Cardiac biomarkers are also elevated due to myocarditis. The 
incidence of elevated cardiac troponin I in patients with viral or idiopathic acute pericarditis 
has been reported to be 32.2%; of these patients 23.7% had a troponin I level at admission 
higher than those seen in myocardial infarction [28]. Elevated cardiac biomarkers in 
pericardial disease are not unusual and further complicate the diagnosis, raising suspicion 
for alternative diagnoses including myocardial infarction [29]. A study by Machdo et. al. 
concluded that perimyocarditis has a higher cardiac mortality than pericarditis [30]. This 
illustrates the importance of checking cardiac markers in all patients presenting with 
pericarditis. Studies also showed that elevated troponin is more common than elevated 
CKMB [31, 32]. The sole increase in troponin without other cardiac markers might represent 
a mild degree of myocardial injury. 
5. Electrocardiography 
Because the pericardium is electrically inert, EKG changes found in patients with acute 
pericarditis are suggestive of an underlying myocardial involvement. The typical EKG 
evolution is seen in up to 60 % of cases of acute pericarditis [26]. EKG may reveal sinus 
tachycardia, diffuse ST segment elevation that is concave upwards involving any lead 
except aVR and V1. In pericarditis, T wave inversion occurs only after the elevated ST 
segment returns to baseline. ST-segment elevation associated with pericarditis should not 
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result in the reciprocal depressions in aVL that accompany inferior MI, although this may 
not apply in some cases of localized pericarditis [33]. The most specific EKG finding for 
acute pericarditis is PR segment depression (PR segment elevation in aVR) which is 
considered an early EKG marker in the evolution of acute pericarditis. PR segment 
depression is due to subepicardial atrial injury and is present in more than 60 % of the 
patients. Acute pericarditis causes characteristic EKG changes that typically evolve through 
4 stages as demonstrated in table 2. 
 
Stage 1 
 
Occurs during the first few 
days of pericardial 
inflammation and may last 
up to 2 weeks 
-  Widespread concave upward ST segment 
elevation except in leads aVR and V1 
- Ratio of ST segment elevation to the T-wave 
amplitude in lead V5 or V6 is ≥ 0.25 
- PR segment depression 
- Absence of reciprocal ST changes 
Stage 2 
 
Occurs hours to days after 
initial symptoms and may 
last from days to several 
weeks 
-  ST segment returns to baseline 
- In the early phase, the J point returns to 
baseline while T waves are still upright and in 
the late phase T waves becomes flattened or 
even inverted 
Stage 3  
 
Begins between the second 
and third week and may 
continue for several weeks 
-  Diffuse T wave inversion 
Stage 4 
 
May last from days up to 3 
months 
- Resolution of T wave inversion and EKG 
returns back to baseline. 
-  Rarely T wave in nversions may persist 
indefinitely (chronic pericarditis). 
Table 2. The 4 Electrocardiographic stages of acute pericarditis. 
Nevertheless, perimyocarditis can present with focal instead of diffuse ST segment elevation 
mimicking transmural myocardial infarction. This, in addition to the presence of chest pain 
and elevated cardiac biomarkers can make the differentiation of increasing difficulty. This is 
important because fatal complications can occur if thrombolytic therapy is administered for 
a patient with acute pericarditis, or if a diagnosis of transmural myocardial infarction is 
missed. Omar et al. demonstrated a similar scenario where an EKG of a patient presenting 
with chest pain revealed focal ST segment elevation (figure 1) and the cardiac biomarkers 
were elevated mimicking STEMI. [34] Careful history taking, EKG interpretation and urgent 
echocardiogram favored the diagnosis of acute perimyocarditis. 
Previous studies have reported the use of thrombolytic therapy for what was later 
determined to be acute pericarditis [35, 36]. The utilization of urgent coronary angiography 
is not uncommon in patients with acute perimyocarditis. Salisbury and colleagues described 
the frequency of urgent coronary angiography in 238 patients with a final diagnosis of acute 
pericarditis to be 16.8 % [37]. 
6. Echocardiography 
Echocardiography looking for pericardial effusion and regional wall motion abnormalities is 
mandatory to help in making the diagnosis and excluding other serious differentials. Imazio 
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Fig. 1. Concave upward ST segment elevation in leads II, III, Avf, V5 and V6 in a patient 
with perimyocarditis. Notice the focal pattern of ST segment elevation (inferolateral leads) 
thereby mimicking transmural myocardial infarction. Adapted from Omar et. al. [34]. 
and collegues found that pericardial effusions are present in approximately 60% of cases of 
acute pericarditis, with 80% being mild, 10% being moderate, and 10% being severe [26]. 
Pericardial effusion was present in 38.1% of patients in the ST segment elevation group and 
73.5% of the patients in the non ST segment elevation and was explained by the tendency of 
the larger pericardial effusions to decrease voltage including the magnitude of ST segment 
elevation [26]. The presence of regional wall motion abnormalities favors an ischemic 
process rather than acute pericarditis. Another potential echocardiographic finding in 
perimyocarditis is transient myocardial thickening (figure 2 and 3) which is due to 
interstitial edema and its presence likely predicts a poor prognosis as it has been associated 
with a fulminant course [38]. In a series of 25 patients with acute myocarditis who 
underwent echocardiogram and endomyocardial biopsy, a significant decrease in 
myocardial thickness was observed between the acute and the convalescent phase. The 
reduction of the edema shown by the biopsy was also significant [39]. 
 
 
Fig. 2. Echocardiogram on admission. Parasternal long axis view (A) and short axis (B) in 
diastole. There is an asymmetrical thickening of the posterior wall involving the posterior 
papillary muscle, and slight pericardial effusion. Adapted from reference number 38 with 
permission. 
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Fig. 3. Echocardiogram 5 days after admission. Parasternal long axis view (A) and short axis 
(B) in diastole. Normalization of the myocardial thickness in the posterior wall and posterior 
papillary and resolution of the pericardial effusion can be seen. Adapted from reference 38 
with permission. 
7. CT angiography 
Another non-invasive diagnostic tool in patients presenting with chest pain, ST segment 
elevation and elevated cardiac biomarkers is the use of the 64-slice coronary CT 
angiography (CCTA) which is a reliable test that can be utilized in patients with low to 
intermediate pretest probability for coronary artery disease. Shturman et. al. used the 64-
slice CCTA to rule out coronary artery disease in a case of perimyocarditis mimicking 
myocardial infarction [40]. This simple noninvasive test and can avert the unnecessary need 
for coronary angiography or thrombolytic therapy for a presumed STEMI. Recently, 
Computed tomographic angiography (CTA) “triple rule out” protocol has been utilized in 
the emergency department for patients presenting with acute chest pain to differentiate 
between pulmonary embolism, aortic dissection and acute coronary syndrome. Compared 
with the usual radiation dose of a standard 64-slice CCTA, the effective radiation dose of a 
"triple rule-out" scan is often increased by 50% which should limit its unrestricted use. 
Takakuwa et. al. reported the successful use of the "triple rule-out" scan in diagnosing acute 
perimyocarditis (figure 4) and excluding other serious etiologies as acute coronary 
syndrome, aortic dissection and pulmonary embolism [41]. 
8. Cardiac magnetic resonance imaging 
In perimyocarditis, gadolinium contrast MRI is useful to confirm the diagnosis by detecting 
an area of delayed contrast-enhancement, to evaluate the severity of inflammation in the 
acute stage as well as to determine the extent of fibrosis in the pericardium and myocardium 
[42]. The normal pericardium is observed as an area of low intensity on T1-weighted images 
and T2-weighted images [43]. In acute pericarditis, the inflamed pericardium is thickened 
and appears as an area of medium to high intensity with delayed contrast-enhancement 
recognized in the swollen pericardium which extends to the subepicardial myocardium 
affected by myocarditis [42]. The delayed enhancement in cardiac magnetic resonance 
(CMR) is explained by the leaking of the contrast media into the interstitial space due to 
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Fig. 4. Four chamber view (left). TRO study demonstrating mild-to-moderate pericardial 
effusion surrounding the heart. Left anterior oblique view (right) optimized to visualize the 
full length of the RCA.  PE - pericardial effusion, RV - right ventricle, LV - left ventricle, 
LAD - left anterior descending coronary artery. Adapted with modification from reference 
number 41 with permission. 
inflammation. As it stays out of the vessel, it cannot be washed away and is held for a longer 
time allowing it to be seen in the delayed enhancement images (figure 5) [44]. 
 
 
Fig. 5. Four chamber long-axis views. (A) Cardiac magnetic gadolinium delayed 
enhancement showing subepicardial hyperenhancement (arrow). (B) Cardiac CT delayed 
enhancement (arrows). Adapted from reference 44 with permission from Elsevier.  
Cardiac magnetic resonance can also be a tool to differentiate between acute 
perimyocarditis and myocardial infarction. In acute myocarditis, myocardial late 
gadolinium enhancement is present in up to 88% of cases [45,46] which characteristically 
has patchy distribution not conforming to any particular coronary artery territory and is 
usually in the subepicardial and not the subendocardial layer [47] differentiating it from 
myocardial infarction.  
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9. Endomyocardial biopsy 
Myocarditis may be focal or diffuse affecting any or all cardiac chambers. Although biopsy 
is the gold standard for the diagnosis, it is of limited utility especially in acute myocarditis, 
because of the patchy nature of active inflammation. In a series of over 2,000 patients with 
clinically suspected myocarditis, endomyocardial biopsy was only positive in 10% of the 
cases [48-50]. Given the potential risks of biopsy and the limited value it offers, its use 
should be limited to the patients with left ventricular dysfunction unresponsive to 
conventional therapy [51]. 
The various histologic patterns of myocarditis include either lymphocytic (including viral 
and autoimmune forms), eosinophilic (in which hypersensitivity myocarditis is the most 
common, followed by cases of hypereosinophilic syndrome), granulomatous (sarcoid and 
giant cell myocarditis), neutrophilic (bacterial, fungal, and early forms of viral myocarditis), 
and reperfusion type/contraction band necrosis (present in catecholamine-induced injury 
and reperfusion injury). Figure 6 represents the microscopic picture of acute perimyocarditis 
after diphtheria-tetanus vaccination. 
 
 
Fig. 6. Right ventricular endomyocardial biopsy.  A . Haematoxylin-eosin, original 
magnification 200x: Diffuse interstitial oedema with scattered inflammatory cells.  B.  
Immunohistochemical staining with anti-CD45 antibody, original magnification 400x:  
Lymphocyte inflammatory infiltrate associated with myocyte damage.  C.  Mallory triple 
stain, original magnification 200x: minimal interstitial fibrosis mixed with interstitial 
oedema.  D.  Haematoxylin-eosin, original magnification 200x: One focus of interstitial 
haemorrhage. Adapted from Journal of Chinese Clinical Medicne;2008,9;Vol.3,No.9. [24] 
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10. Management 
As earlier described, perimyocarditis is a combination of both pericardial inflammation and 
myocardial damage. Treatment should therefore target both pathologies. Because 
myocarditis is a more serious diagnosis owing to the potential of serious ventricular 
arrhythmias and heart failure, the diagnosis of myocarditis is deemed more important. 
Acute pericarditis usually runs a smooth and benign course after empiric treatment with 
NSAID and routine hospitalization in most cases is not necessary. Perimyocarditis on the 
other hand has higher incidence of complications and is one of the indications for 
hospitalization. Checking the levels of cardiac biomarkers and echocardiography is 
therefore mandatory in any case of acute pericarditis. Imazio et. al. identified certain poor 
prognostic predictors that are more frequently associated with an increased risk of short 
term complications and therefore an indication for hospitalization [26]. Table 3 lists various 
indications for hospitalization of patients presenting with acute pericarditis  
 
Indications for Hospitalization of Patients with Acute Pericarditis 
1. Anticoagulation therapy
2. Body temperature greater than 100.4° F (38° C) 
3. Echocardiographic findings of a large pericardial effusion 
4. Findings of cardiac tamponade (i.e., hypotension and neck vein distention)                          
5. History of trauma and compromised immune system 
6. Myopericarditis 
7. Troponin I elevation 
Table 3. Indications for Hospitalization of Patients with Acute Pericarditis. (adapted from 
reference 26) 
There are certain scenarios when perimyocarditis present with focal EKG signs suggestive of 
STEMI. This can be challenging especially in developing countries where thrombolytic 
therapy is the mainstay of management of STEMI. In patients with acute pericarditis, 
thrombolytic therapy can be detrimental because of the risk of cardiac tamponade [52, 53]. 
Although the use of anticoagulants in patients with acute pericarditis is deemed 
unfavorable, in their study on 274 consecutive cases of idiopathic or viral acute pericarditis, 
Imazio and colleagues concluded that neither the use of heparin, anticoagulants nor 
glycoprotein IIb/IIIa inhibitors is associated with an increased risk of cardiac tamponade. 
[54] Risk factors for complications in that study included the lack of complete response to 
aspirin or NSAID (OR = 14.6, 95% CI 6.1 to 35.1; P = 0.001), or corticosteroid use (OR = 3.0, 
95% CI 1.1 to 8.9; P = 0.048). 
The mainstay of therapy for acute pericarditis is NSAID (class 1 recommendation in 2004 
ESC guidelines). The goal of NSAID is to reduce pain and inflammation. Ibuprofen might be 
preferred because of its rare side effects, favorable impact on coronary artery blood flow and 
large dose range from 1200 to 1800 mg daily [55]. Aspirin can also be used in anti-
inflammatory doses (up to 800 mg every 6 hours). Dose tapering is preferred to avoid 
recurrence. Gastric protection is mandatory and should be commenced in all patients. In 
perimyocarditis, NSAID should be used cautiously because in animal models they were 
shown to enhance the myocarditic process and may increase mortality [56-58]. Lower anti-
inflammatory doses should therefore be considered whenever possible in perimyocarditis 
and its main use is to control symptoms. Failure to respond to NSAID within one week 
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(indicated by persistence of fever, new pericardial effusion, or continuing chest pain) 
indicates that a cause other than viral is responsible and should be searched for. Although 
colchicines can be used alone or in conjunction with NSAID in treatment and prevention of 
recurrent pericarditis, there is lack of data regarding its benefit in perimyocarditis [59]. 
The use of corticosteroids was found to be an independent risk factor for recurrence of acute 
pericarditis [60, 61] because of their ability to promote viral replication [62, 63]. Its use 
should therefore be restricted for those with autoimmune disease or in cases refractory to 
NSAID and colchicine and a specific cause has not been found. Despite the long list of 
pathogens, in most cases, a specific etiology for acute perimyocarditis can’t be determined. 
In instances where an underlying treatable cause is confirmed, treatment of the target 
organism should be commenced. After hospital discharge, patient should be followed for 
several weeks to rule out the development of heart failure or subclinical left ventricular 
dysfunction. All patients should be advised to avoid strenuous exercise during the recovery 
phase (4-6 weeks) which can increase the risk of ventricular arrhythmias. 
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